<DOC>
	<DOCNO>NCT00122668</DOCNO>
	<brief_summary>The aim randomize study compare occurrence lipoatrophy HIV-1 infect , naive patient receive either nucleoside reverse transcriptase inhibitor ( NRTI ) -sparing antiretroviral therapy non-nucleoside reverse transcriptase inhibitor ( NNRTI ) boost protease inhibitor ( PI ) , standard antiretroviral therapy 2 NRTI plus either PI NNRTI . Lipoatrophy evaluate measurement fat volume compute tomography ( CT ) -scan DEXA ( Dual Energy X-ray Absorptiometry ) .</brief_summary>
	<brief_title>Evaluation Occurrence Lipoatrophy HIV-1 Infected Naive Patients</brief_title>
	<detailed_description>The study compare rate occurrence lipoatrophy ARVnaive HIV-1 infect patient receive either NRTI-sparing antiretroviral therapy NRTI boost PI , standard antiretroviral therapy 2 NRTI plus PI NNRTI . Patients randomize ( 2:1:1 ) either PI+NNRTI ( Gp1 ) standard therapy , 2NRTI+ either PI ( Gp2 ) + NNRTI ( Gp3 ) . The study-treatment lopinavir/r 100/400mg bid indinavir/r 100/400mg bid PI-class , NNRTI-class , efavirenz nevirapine NRTIs except D4T DDC usual dosage . Lipoatrophy evaluate evolution subcutaneous fat limb measure DEXA ( Dual Energy X-ray Absorptiometry ) CT-scan thigh baseline W96 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Confirmed HIV1infected diagnosis Naive antiretroviral treatment Plasma viral load ( VL ) 5000 copies/ ml CD4 count equal 350/mm3 CD4 350/mm3 VL equal 100 000 copies/ml Written , inform consent approval local human research ethic committee Acute opportunistic infection Pregnancy breast feed Cytotoxic systemic chemotherapy except Kaposi sarcoma Patient infect B C hepatitis require specific treatment begin study Polynuclear neutrophils 750/mm3 Hemoglobin 8 g/dl Platelets 20 000/mm3 Creatinine level 1.5 ( upper normal ) UN ASAT , ALAT , bilirubin level 3 UN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>HIV-Associated Lipodystrophy Syndrome</keyword>
	<keyword>HIV infection</keyword>
</DOC>